[go: up one dir, main page]

PL2640467T3 - Krystaliczna postać inhibitora interakcji MDM2/4 i p53 - Google Patents

Krystaliczna postać inhibitora interakcji MDM2/4 i p53

Info

Publication number
PL2640467T3
PL2640467T3 PL11790916T PL11790916T PL2640467T3 PL 2640467 T3 PL2640467 T3 PL 2640467T3 PL 11790916 T PL11790916 T PL 11790916T PL 11790916 T PL11790916 T PL 11790916T PL 2640467 T3 PL2640467 T3 PL 2640467T3
Authority
PL
Poland
Prior art keywords
mdm2
inhibitor
interaction
crystalline form
crystalline
Prior art date
Application number
PL11790916T
Other languages
English (en)
Inventor
Joerg Berghausen
Haixia Ren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45093718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2640467(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2640467T3 publication Critical patent/PL2640467T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11790916T 2010-11-19 2011-11-17 Krystaliczna postać inhibitora interakcji MDM2/4 i p53 PL2640467T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2010078927 2010-11-19
PCT/EP2011/070385 WO2012066095A1 (en) 2010-11-19 2011-11-17 Crystalline form of an inhibitor of mdm2/4 and p53 interaction
EP11790916.8A EP2640467B1 (en) 2010-11-19 2011-11-17 Crystalline form of an inhibitor of mdm2/4 and p53 interaction

Publications (1)

Publication Number Publication Date
PL2640467T3 true PL2640467T3 (pl) 2015-05-29

Family

ID=45093718

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11790916T PL2640467T3 (pl) 2010-11-19 2011-11-17 Krystaliczna postać inhibitora interakcji MDM2/4 i p53

Country Status (34)

Country Link
US (2) US8969351B2 (pl)
EP (1) EP2640467B1 (pl)
JP (1) JP5667308B2 (pl)
KR (1) KR101561750B1 (pl)
AR (1) AR083905A1 (pl)
AU (1) AU2011331095B2 (pl)
BR (1) BR112013011966A2 (pl)
CA (1) CA2816810A1 (pl)
CO (1) CO6801719A2 (pl)
CU (1) CU24130B1 (pl)
CY (1) CY1116002T1 (pl)
DK (1) DK2640467T3 (pl)
EC (1) ECSP13012628A (pl)
ES (1) ES2528376T3 (pl)
GT (1) GT201300132A (pl)
HR (1) HRP20150231T1 (pl)
IL (1) IL226182A0 (pl)
MA (1) MA34666B1 (pl)
ME (1) ME02099B (pl)
MX (1) MX336634B (pl)
MY (1) MY160880A (pl)
NZ (1) NZ610296A (pl)
PE (1) PE20140420A1 (pl)
PH (1) PH12013500979A1 (pl)
PL (1) PL2640467T3 (pl)
PT (1) PT2640467E (pl)
RS (1) RS53770B1 (pl)
RU (1) RU2013127661A (pl)
SG (1) SG190186A1 (pl)
SI (1) SI2640467T1 (pl)
SM (1) SMT201500059B (pl)
TW (1) TWI520950B (pl)
WO (1) WO2012066095A1 (pl)
ZA (1) ZA201303155B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
BR112015029491A2 (pt) 2013-05-27 2017-07-25 Novartis Ag derivados de imidazopirrolidinona e seu uso no tratamento de doença
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
MX2015016425A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
EP3086810A2 (en) * 2013-12-23 2016-11-02 Novartis AG Pharmaceutical combinations
KR102283895B1 (ko) * 2013-12-23 2021-07-30 노파르티스 아게 제약 조합물
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
CA2992221C (en) 2015-08-28 2023-06-27 Novartis Ag Mdm2 inhibitors and combinations thereof
US20180318275A1 (en) * 2015-08-28 2018-11-08 Novartis Ag Combination therapy using pi3k inhibitor and mdm2 inhibitor
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
KR101838687B1 (ko) 2016-01-26 2018-03-15 한국생명공학연구원 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3541387B1 (en) 2016-11-15 2021-04-21 Novartis AG Dose and regimen for hdm2-p53 interaction inhibitors
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
EP3681503A1 (en) 2017-09-12 2020-07-22 Novartis AG Protein kinase c inhibitors for treatment of uveal melanoma
CN111163781B (zh) 2017-10-12 2023-05-16 诺华股份有限公司 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
JPS4822715B1 (pl) 1970-12-28 1973-07-07
JPS5427356B2 (pl) 1972-03-31 1979-09-10
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4258187A (en) 1977-06-16 1981-03-24 E. I. Du Pont De Nemours And Company Process for preparing quinazolinone oxides
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3420799A1 (de) 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (pl) 1992-04-03 1994-06-21 Ciba Geigy Ag
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3088018B2 (ja) 1995-03-30 2000-09-18 ファイザー・インコーポレーテッド キナゾリン誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
EA001428B1 (ru) 1995-07-06 2001-02-26 Новартис Аг Пирролопиримидины и фармацевтические композиции, включающие эти соединения
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN1145614C (zh) 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ333609A (en) 1996-07-05 2000-08-25 Cancer Res Campaign Tech Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
JP2002513445A (ja) 1996-09-06 2002-05-08 オブデュキャット、アクチボラグ 導電材料内の構造の異方性エッチング方法
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003235504A1 (en) 2002-05-13 2003-11-11 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
SI1663185T1 (sl) 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
WO2006097337A2 (en) 2005-03-18 2006-09-21 Onepharm Gmbh 11β-HYDROXYSTEROID DEHYDROGENASES
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones

Also Published As

Publication number Publication date
WO2012066095A1 (en) 2012-05-24
JP5667308B2 (ja) 2015-02-12
HK1184091A1 (en) 2014-01-17
DK2640467T3 (en) 2015-03-02
NZ610296A (en) 2014-08-29
ME02099B (me) 2016-02-20
CU20120098A7 (es) 2012-10-15
AU2011331095A1 (en) 2013-05-30
MY160880A (en) 2017-03-31
SG190186A1 (en) 2013-06-28
KR101561750B1 (ko) 2015-10-19
EP2640467A1 (en) 2013-09-25
AU2011331095B2 (en) 2016-03-10
CO6801719A2 (es) 2013-11-29
JP2013542968A (ja) 2013-11-28
MX2013005631A (es) 2013-07-05
KR20130087572A (ko) 2013-08-06
RS53770B1 (en) 2015-06-30
ZA201303155B (en) 2014-01-29
PE20140420A1 (es) 2014-04-02
US9073898B2 (en) 2015-07-07
PT2640467E (pt) 2015-03-12
CY1116002T1 (el) 2017-04-26
TWI520950B (zh) 2016-02-11
RU2013127661A (ru) 2014-12-27
EP2640467B1 (en) 2014-12-17
SMT201500059B (it) 2015-05-05
AR083905A1 (es) 2013-04-10
CA2816810A1 (en) 2012-05-24
TW201302725A (zh) 2013-01-16
SI2640467T1 (sl) 2015-04-30
GT201300132A (es) 2014-06-09
PH12013500979A1 (en) 2018-04-11
ECSP13012628A (es) 2013-07-31
ES2528376T3 (es) 2015-02-09
CU24130B1 (es) 2015-09-29
IL226182A0 (en) 2013-07-31
MX336634B (es) 2016-01-26
HRP20150231T1 (xx) 2015-03-27
BR112013011966A2 (pt) 2016-08-30
US20130245036A1 (en) 2013-09-19
MA34666B1 (fr) 2013-11-02
US20120129871A1 (en) 2012-05-24
US8969351B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
IL226182A0 (en) Crystalline form of inhibitor interaction@between@B@4mdm@and–@p
IL263729A (en) Preparations and methods for removing biofilms
IL246600B (en) Heterocyclic compounds and their use
EP2533783B8 (en) COMPOUNDS AND METHODS for the inhibition of HDAC
ZA201301120B (en) Heterocyclic compound and use thereof
EP2637669A4 (en) Heterocyclic compounds and their use
IL222288A0 (en) Heterocyclic compounds and their uses
ZA201207937B (en) Sarms and method of use thereof
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2539348A4 (en) CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
IL223205B (en) Crystal form of benzylbenzene inhibitor 2sglt
ZA201300388B (en) Compositions and methods for inhibition of the jak pathway
ZA201206456B (en) Uses of dgati inhibitors
SI2203440T1 (sl) Inhibitorji interakcije med MDM2 in P53
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
ZA201300065B (en) Crystal of amide compound
EP2618844A4 (en) ORAL FORMABLE COMPOSITION AND METHOD FOR THEIR PRODUCTION AND USE
GB201020357D0 (en) Compounds and methods of making the same
ZA201205565B (en) Ester compound and use thereof
SG10201509157QA (en) Compound for increasing kinase active and application thereof
TWM386036U (en) Structure of freshness-maintaining box
HK1187278A (en) Compositions and methods for the removal of biofilms
TWM401619U (en) Storage box capable of being assembled and detached
HK1188445A (en) Hepatitis c inhibitors and uses thereof
TWM402196U (en) Structural improvement of memorial stamp having sealed article